Clinical assessment of tacrolimus therapy in lupus nephritis: One-year follow-up study in a single center

Nephron - Clinical Practice

Volumn 113, Issue 4, 2009, Pages

  Asamiya, Yukari ^a   Uchida, Keiko ^a   Otsubo, Shigeru ^a   Takei, Takashi ^a   Nitta, Kosaku ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Complement; Lupus nephritis; Proteinuria; Tacrolimus

Indexed keywords

CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; METHYLPREDNISOLONE; MIZORIBINE; PREDNISOLONE; TACROLIMUS;

ADULT; AGED; ARTICLE; BACTERIAL MENINGITIS; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CREATININE BLOOD LEVEL; DISORDERS OF CARBOHYDRATE METABOLISM; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; FOLLOW UP; HERPES ZOSTER; HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; MAINTENANCE THERAPY; MALE; NEUROTOXICITY; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; SIDE EFFECT; TREMOR; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; MALE; MIDDLE AGED; TACROLIMUS; TREATMENT OUTCOME;

EID: 69549095650     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000235952     Document Type: Article

References (27)

1. Bernatsky S, Boivin JF, Joseph L, et al: Mortality in systemic lupus erythematosus. Arthritis Rheum 2006; 54: 2550-2557.
2. Pollak VE, Pirani CL, Schwartz FD: The natural history of the renal manifestations of systemic lupus erythematosus. J Lab Clin Med 1964; 63: 537-550.
3. Austin HA 3rd, Klippel JH, Balow JE, et al: Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986; 314: 614-619.
4. Boumpas DT, Austin HA 3rd, Vaughn EM, et al: Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992; 340: 741-745.
5. Gourley MF, Austin HA 3rd, Scott D, et al: Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med 1996; 125: 549-557.
6. Illei GG, Austin HA, Crane M, et al: Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001; 135: 248-257.
7. Hallegua D, Wallace DJ, Metzger AL, et al: Cyclosporine for lupus membranous nephritis: Experience with ten patients and review of the literature. Lupus 2000; 9: 241-251.
8. Radhakrishnan J, Kunis CL, D'Agati V, et al: Cyclosporine treatment of lupus membranous nephropathy. Clin Nephrol 1994; 42: 147-154.
9. Chan TM, Li FK, Tang CS, et al: Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 2000; 343: 1156-1162.
10. Chan TM, Tse KC, Tang CS, et al: Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005; 16: 1076-1084.
11. Cross J, Dwomoa A, Andrews P, et al: Mycophenolate mofetil for remission induction in severe lupus nephritis. Nephron Clin Pract 2005; 100:c92-c100.
12. Aihara Y, Miyamae T, Ito S, et al: Mizoribine as an effective combined maintenance therapy with prednisolone in child-onset systemic lupus erythematosus. Pediatr Int 2002; 44: 199-204.
13. Tanaka H, Oki E, Tsuruga K, et al: Mizoribine treatment of young patients with severe lupus nephritis: A clinicopathologic study by the Tohoku Pediatric Study Group. Nephron Clin Pract 2008; 110:c73-c79.
14. Kobert SM, Lewis EJ, Schwartz MM, et al: Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group. Am J Kidney Dis 2000; 35: 904-914.
15. Mok CC, Tong KH, To CH, et al: Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: An open-labeled pilot study. Kidney Int 2005; 68: 813-817.
16. Politt D, Heintz B, Floege J, et al: Tacrolimus (FK506) based immunosuppression in severe systemic lupus erythematosus. Clin Nephrol 2004; 62: 49-53.
17. Tse KC, Lam MF, Tang SCW, et al: A pilot study on tacrolimus treatment in membranous or quiescent lupus nephritis with proteinuria resistant to angiotensin inhibitor or blockade. Lupus 2007; 16: 46-51.
18. Tan EM, Cohen AS, Fries JF, et al: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
19. Weening JJ, D'Agati VD, Schwartz MM, et al: The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004; 15: 241-250.
20. Suzuki K, Kameda H, Amano K, et al: Single center prospective study of tacrolimus efficacy and safety in treatment of rheumatoid arthritis. Rheumatol Int 2009; 29: 431-436.
21. Tamura K, Kobayashi M, Hashimoto K, et al: A highly sensitive method to assay FK-506 levels in plasma. Transplant Proc 1987; 19: 23-29.
22. Taylor PJ, Morris RG: Tacrolimus measurement by microparticle enzyme immunoassay. Ther Drug Monit 2003; 25: 259-260.
23. Moroni G, Quaglini S, Maccario M, et al. 'Nephritic flares' are predictors of bad longterm renal outcome in lupus nephritis. Kidney Int 1996; 50: 2047-2053.
24. Aran AA, Putterman C: Treatment of lupus nephritis: Facing the era of immunotherapy. Panminerva Med 2008; 50: 235-245.
25. Ranchin B, Fargue S: New treatment strategies for proliferative lupus nephritis: Keep children in mind. Lupus 2007; 16: 684-691.
26. Duddridge M, Powell RJ: Treatment of severe and difficult cases of systemic lupus erythematosus with tacrolimus. A report of three cases. Ann Rheum Dis 1997; 56: 690-692.
27. Nankivell BJ, Borrows RJ, Fung CL, et al. Calcineurin inhibitor nephrotoxicity: Longitudinal assessment by protocol histology. Transplantation 2004; 78: 557-565.